ABCB1 and prostate cancer: Prostatectomies from 336 chemo-naïve castration resistant prostate cancer (CRPC) patients (Kristensen et al., 2018) (Table 1), were used to assess the potential of ABCB1 expression as a predictive biomarker for DTX resistance in prostate cancer (Figure 1).